Which company received FDA approval in 2022 for a gene therapy to treat a rare g

₹0.0

Question: Which company received FDA approval in 2022 for a gene therapy to treat a rare genetic disorder?

Options:

Correct Answer: Bluebird Bio

Solution:

Bluebird Bio received FDA approval in 2022 for its gene therapy, Zynteglo, to treat beta-thalassemia, a rare genetic blood disorder.

Which company received FDA approval in 2022 for a gene therapy to treat a rare genetic disorder?

Which company received FDA approval in 2022 for a gene therapy to treat a rare genetic disorder?

Step 1: Identify the year 2022.
Step 2: Look for companies that received FDA approval in 2022.
Step 3: Find out which company received approval for a gene therapy.
Step 4: Confirm that Bluebird Bio is the company that received FDA approval.
Step 5: Check the name of the gene therapy approved by Bluebird Bio.
Step 6: Verify that the gene therapy is called Zynteglo.
Step 7: Understand that Zynteglo is used to treat beta-thalassemia, which is a rare genetic blood disorder.

No concepts available.